BECOME A MEMBER
Connect with healthcare professionals around the globe to get the most up-to-date medical cannabis information.
Get Involved
TAKE OUR COURSES
The curriculum brings hands-on practical guidance on how to develop personalized treatment regimens and more.
Cannabis, cannabinoids and reproduction.
Authors: Boram Park, John M. McPartland, Michelle Glass
Prostaglandins, Leukotrienes and Essential Fatty Acids, February 2004
—
In most countries Cannabis is the most widely used illegal drug. Its use during pregnancy in developed nations is estimated to be approximately 10%. Recent evidence suggests that the endogenous cannabinoid system, now consisting of two receptors and multiple endocannabinoid li…
The endocannabinoid-CB receptor system: Importance for development and in pediatric disease.
Authors: Ester Fride
Neuro endocrinology letters, February-April 2004
—
Endogenous cannabinoids (endocannabinoids) and their cannabinoid CB1 and CB2 receptors, are present from the early stages of gestation and play a number of vital roles for the developing organism. Although most of these data are collected from animal studies, a role for cannab…
Two hundred and thirteen cases of marijuana toxicoses in dogs.
Authors: Pawel Janczyk, Caroline W Donaldson, Sharon M. Gwaltney
Veterinary and Human Toxicology, February 2004
—
Marijuana (Cannabis sativa) is a commonly used recreational drug among humans; animals may be exposed following ingestion or accidental inhalation of smoke. From January 1998 to January 2002, 213 incidences were recorded of dogs that developed clinical signs following oral exp…
The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy.
Authors: Melisa J. Wallace, Robert E. Blair, Katherine W. Falenski, Billy R. Martin, Robert J. DeLorenzo
Journal of Pharmacology and Experimental Therapeutics, October 2003
—
Several lines of evidence suggest that cannabinoid compounds are anticonvulsant. However, the anticonvulsant potential of cannabinoids and, moreover, the role of the endogenous cannabinoid system in regulating seizure activity has not been tested in an in vivo model of epileps…
Cannabinoids reduce symptoms of Tourette’s syndrome.
Authors: Kirsten R Müller-Vahl
Expert Opinion on Pharmacotherapy, October 2003
—
Currently, the treatment of Tourette’s syndrome (TS) is unsatisfactory. Therefore, there is expanding interest in new therapeutical strategies. Anecdotal reports suggested that the use of cannabis might improve not only tics, but also behavioural problems in patients with TS…
Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study.
Authors: Igor Grant, Raul Gonzalez, Catherine L. Carey, Loki Natarajan, Tanya Wolfson
Journal of the International Neuropsychological Society, July 2003
—
The possible medicinal use of cannabinoids for chronic diseases emphasizes the need to understand the long-term effects of these compounds on the central nervous system. We provide a quantitative synthesis of empirical research pertaining to the non-acute (residual) effects of…
Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance.
Authors: Kirsten R Müller-Vahl, Heidrun Prevedel, Karen Theloe, Hans Kolbe, et al
Neuropsychopharmacology, February 2003
—
Previous studies provide evidence that marijuana (Cannabis sativa) and delta-9-tetrahydrocannabinol (Delta(9)-THC), the major psychoactive ingredient of marijuana, respectively, are effective in the treatment of tics and behavioral problems in Tourette syndrome (TS). It, there…
Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.
Authors: Louise Arseneault, Mary Cannon, Richie Poulton, Robin Murray, Avshalom Caspi, Terrie E Moffitt
BMJ, 23 November 2002
—
The strongest evidence that cannabis use may be a risk factor for later psychosis comes from a Swedish cohort study which found that heavy cannabis use at age 18 increased the risk of later schizophrenia sixfold. This study could not establish whether adolescent cannabis use w…
Cardiovascular system effects of marijuana.
Authors: Reese T. Jones
The Journal of Clinical Pharmacology, November 2002
—
Marijuana and delta9-tetrahydrocannabinol (THC) increase heart rate, slightly increase supine blood pressure, and on occasion produce marked orthostatic hypotension. Cardiovascular effects in animals are different, with bradycardia and hypotension the most typical response. Ca…
Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease.
Authors: Guy Neff, Christopher O’Brien, Rajender Reddy, Nora Bergasa, Arie Regev, et al
The American Journal of Gastroenterology, August 2002
—
Pruritus due to cholestatic liver disease can be particularly difficult to manage and frequently is intractable to a variety of medical therapies. The aim of our study is to evaluate the efficacy of delta-9-tetrahydrocannabinol (delta-9-THC) for intractable cholestatic related…
Response to Early AED Therapy and Its Prognostic Implications.
Authors: Jacqueline A. French
Epilepsy Currents, May 2002
—
Determining the prognosis of patients when they first present with epilepsy is a difficult task. Several clinical studies have shed light on this very important topic. Potential predictors of the refractory state, including seizure etiology, duration of epilepsy before treatme…
Cannabinoids and brain injury: therapeutic implications.
Authors: Raphael Mechoulam, David Panikashvili, Esther Shohami
Trends in Molecular Medicine, February 2002
—
Mounting in vitro and in vivo data suggest that the endocannabinoids anandamide and 2-arachidonoyl glycerol, as well as some plant and synthetic cannabinoids, have neuroprotective effects following brain injury. Cannabinoid receptor agonists inhibit glutamatergic synaptic tran…